InvestorsHub Logo
Followers 25
Posts 1207
Boards Moderated 0
Alias Born 12/11/2008

Re: Ekd post# 17775

Sunday, 11/29/2020 8:36:24 PM

Sunday, November 29, 2020 8:36:24 PM

Post# of 36556
Translated...

Kyungdong Pharmaceutical acquires permission to export raw materials for COVID-19 treatment 'surge'

[Asia Times = Reporter Kim Ji-ho] The news of the export license of 'Bushiramin', which is being developed overseas as a treatment for Corona 19, is on the rise by Kyungdong Pharmaceutical.

As of 9:34 am on the 30th, Kyungdong Pharmaceutical is recording 13,150 won, a 21.20% increase from the previous trading day.

According to industry sources, Kyungdong Pharmaceutical received a permit for export of bushramin raw materials from the Ministry of Food and Drug Safety on the 26th.

Bushramin is a treatment for rheumatoid arthritis, recently approved by the US Food and Drug Administration (FDA) for a phase 3 clinical trial by Canadian pharmaceutical company Revive Therapeutics to develop it as a treatment for COVID-19.

Like remdesivir, bushramin is expected to re-create a drug for the treatment of Corona 19.

Kyungdong Pharm Co stock is rising in S. Korea. The company received approval for exporting bucillamine on 11/26. The article mentions phase 3 trial by Revive. Click Google Translate and you should be able to read the article.

https://asiatime.co.kr/news/newsview.php?ncode=1065573304574349